BIAL's Groundbreaking Presentation at GBA1 Meeting 2025
BIAL, a biopharmaceutical company specializing in neuroscience and rare diseases, is set to present its innovative compound, BIA 28-6156, at the upcoming GBA1 Meeting. The presentation will shed light on the potential of this therapy to change the landscape of Parkinson's disease treatment, particularly for patients suffering from GBA1 mutations.
ACTIVATE Study Overview
The ACTIVATE study is a crucial Phase II clinical trial that aims to assess the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156. This study specifically targets patients with Parkinson's disease who have a specific mutation in the glucocerebrosidase 1 (GBA1) gene. BIAL's commitment to advancing treatment in this area demonstrates significant dedication to addressing unmet medical needs within the neurological community.
Insightful Presentation Content
The oral presentation will take place in the 'Small molecules targeting GBA1' session, highlighting the intricate details of the study's design, recruitment challenges, and the current status of clinical trials. Raquel Costa, who leads the study, expresses enthusiasm for the opportunity to contribute valuable insights to the Parkinson's community during the conference.
BIA 28-6156 Explained
BIA 28-6156 is an innovative small molecule designed for once-daily oral administration. As a first-in-class allosteric activator of beta-glucocerebrosidase (GCase), it holds great promise in directly addressing the root cause of GBA-PD. By enhancing GCase activity, it aims to re-establish the recycling of sphingolipids, which are crucial in mitigating the disease's impact.
The ACTIVATE study has thus far enrolled 273 patients with genetically verified GBA-PD across multiple sites. With several participants already completing the trial, BIAL anticipates the release of topline data in the near future, aiming to pave the way for a groundbreaking treatment option for GBA-PD sufferers.
Presentation Details You Should Know
The presentation details for the GBA1 Meeting are as follows:
- Date: June 5, 2025
- Time: 12:00 - 12:20 PM
- Session: Small molecules targeting GBA1 - Session 2
- Presenter: Raquel Costa, Senior Manager, Clinical Operations, BIAL
- Location: Delta Hotels, Montreal
About BIAL
BIAL is a pioneering pharmaceutical company with a robust history spanning over a century. The organization is dedicated to enhancing healthcare through groundbreaking research and development, channeling over 20% of its revenues annually into therapeutic innovation.
With a firm foothold in Europe, BIAL maintains its primary manufacturing and research center in Portugal while also operating subsidiaries across several key locations, ensuring the provision of healthcare solutions worldwide. With its unwavering focus on neurosciences and rare diseases, BIAL is committed to making impactful changes in clinical outcomes for patients in dire need.
Today, BIAL's medications are present in over 50 countries, reflecting the organization's determination to improve the lives of those affected by severe diseases.
Frequently Asked Questions
What is BIA 28-6156?
BIA 28-6156 is a first-in-class small molecule developed to enhance GCase activity in patients with GBA-PD, intending to modify the disease's underlying causes.
When will the ACTIVATE study's results be available?
Topline data from the ACTIVATE study is expected to be released in the second quarter of 2026.
Where will the GBA1 Meeting 2025 take place?
The meeting will be held in Montreal, specifically at the Delta Hotels.
Who is leading the ACTIVATE study?
The study is led by Raquel Costa, who is a Senior Manager in Clinical Operations at BIAL.
How long has BIAL been in operation?
BIAL has a rich history, having been founded over a century ago and focusing on innovative pharmaceutical development.
